Cell Therapeutics buoyed by EU launch of Pixuvri but US plans yet to solidify
This article was originally published in Scrip
Executive Summary
Cell Therapeutics began its EU commercial launch of Pixuvri (pixantrone) for the treatment of refractory non-Hodgkin's lymphoma in the Nordic region and will add larger markets later in 2012 and into 2013 as the Seattle, US-based company negotiates pricing with government health programmes.